tiprankstipranks
Trending News
More News >
Idexx Laboratories (CH:IX1)
:IX1
Switzerland Market
Advertisement

Idexx Laboratories (IX1) Earnings Dates, Call Summary & Reports

Compare
0 Followers

Earnings Data

Report Date
Feb 09, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
2.36
Last Year’s EPS
2.12
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 03, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
IDEXX Laboratories reported strong financial performance and increased its full year guidance, driven by gains in CAG Diagnostics and international markets. However, challenges such as a decline in U.S. clinical visits and wellness visits persisted, along with impacts from foreign exchange and rapid assay revenue shifts.
Company Guidance
During the IDEXX Laboratories Third Quarter 2025 Earnings Conference Call, the company reported a strong financial performance with several key metrics highlighted. Revenue increased by 13% as reported and 12% organically, driven by over 10% organic growth in Companion Animal Group (CAG) Diagnostics recurring revenues, including an 8% increase in the U.S. and double-digit growth internationally. The company achieved a 71% organic growth in CAG instrument revenues, with over 1,750 IDEXX InVue Dx analyzers placed. Operating margins improved by 120 basis points, contributing to a 15% EPS growth on a comparable basis, resulting in an EPS of $3.40 for the quarter. The full-year revenue outlook was increased by $43 million at the midpoint, with an updated range of $4.270 billion to $4.300 billion, reflecting an overall reported revenue growth of 9.6% to 10.3%. The company's updated full-year EPS guidance is $12.81 to $13.01 per share, indicating a $0.33 increase per share at the midpoint. International CAG Diagnostics recurring revenue grew by 14% organically, with a 1% benefit related to equivalent days. IDEXX's innovation strategy continues to drive growth, as evidenced by strong placements of InVue Dx and the growing adoption of Cancer Dx, which has reached nearly 5,000 customers.
Strong Revenue Growth
IDEXX reported a 13% increase in revenue as reported, with 12% organic growth, driven by a 10% gain in CAG Diagnostics recurring revenues, including significant growth in both U.S. and international regions.
EPS and Operating Margin Increase
Earnings per share grew to $3.40, marking a 15% increase. The operating margin also improved by 120 basis points on a comparable basis.
CAG Diagnostics Instrument Revenue Surge
CAG instrument revenues saw a 71% organic growth, supported by over 1,750 IDEXX InVue Dx analyzers placed.
International CAG Diagnostics Growth
International CAG Diagnostics recurring revenue grew 14% organically, reflecting strong volume gains and sustained growth over the past 10 quarters.
Increased Full Year Financial Guidance
IDEXX increased its full year revenue outlook by $43 million at midpoint, expecting overall reported revenue growth of 9.6% to 10.3% and EPS of $12.81 to $13.01 per share.

Idexx Laboratories (CH:IX1) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CH:IX1 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 09, 2026
2025 (Q4)
2.36 / -
2.121
Nov 03, 2025
2025 (Q3)
2.54 / 2.75
2.26721.43% (+0.49)
Aug 04, 2025
2025 (Q2)
2.67 / 2.94
1.97548.77% (+0.96)
May 01, 2025
2025 (Q1)
2.31 / 2.40
2.2755.34% (+0.12)
Feb 03, 2025
2024 (Q4)
1.95 / 2.12
1.87812.93% (+0.24)
Oct 31, 2024
2024 (Q3)
2.17 / 2.27
2.04810.67% (+0.22)
Aug 06, 2024
2024 (Q2)
2.34 / 1.98
2.162-8.61% (-0.19)
May 01, 2024
2024 (Q1)
2.20 / 2.27
2.06410.20% (+0.21)
Feb 05, 2024
2023 (Q4)
1.72 / 1.88
1.6613.17% (+0.22)
Nov 01, 2023
2023 (Q3)
1.92 / 2.05
1.74117.67% (+0.31)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

FAQ

When does Idexx Laboratories (CH:IX1) report earnings?
Idexx Laboratories (CH:IX1) is schdueled to report earning on Feb 09, 2026, Before Open (Confirmed).
    What is Idexx Laboratories (CH:IX1) earnings time?
    Idexx Laboratories (CH:IX1) earnings time is at Feb 09, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Idexx Laboratories stock?
          The P/E ratio of Idexx Laboratories is N/A.
            What is CH:IX1 EPS forecast?
            CH:IX1 EPS forecast for the fiscal quarter 2025 (Q4) is 2.36.
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis